Experimental drug SGI-110 tested for rare tumors, but study stopped early
NCT ID NCT03165721
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tested a drug called SGI-110 (guadecitabine) in people aged 12 and older with certain rare cancers that did not respond to other treatments. The cancers included wild-type GIST (a stomach or intestinal tumor), pheochromocytoma/paraganglioma (adrenal or nerve tumors), and a type of kidney cancer linked to HLRCC. The drug was given as a daily injection for 5 days every 28 days. The study was terminated early after enrolling only 9 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.